The Catalan company ZeClinics, supported by the University Pompeu Fabra of Barcelona and and Barcelona Biomedicine Research Park (PRBB) reached its crowdfunding campaign goal on Capital Cell, a campaign that set the record for the the year’s largest biotech crowdfunding investment in Spain. The company is prevalued at 1M€. After 88 days of campaigning, the company secured 100,000€ by 64 backers for 9.09% equity offered to develop its personalized cancer therapy, ZeOncoTest, a system that investigates how cancer can be replicated in zebrafish to customize the treatment and therapy for cancer patients.
Like many other scientific companies, ZeClinics struggled to find funding to develop new products. In early February, the company opted for crowdfunding, to raise the capital needed to grow the company.
The biotech’s business strengths rely on the highly technical expertise of its founders and researchers, as well as its top-notch research facilities, strategic partnerships and academic collaborations. The startup aims to challenge the traditional drug discovery pipeline by offering a cheaper, faster and more reliable array of customized tests which assess the safety and biomedical relevance of novel molecules using zebrafish.
Capital Cell is a Spanish crowdfunding platform specializing in biotech, helmed by CEO Daniel Oliver, who also serves as the president of Asociación Española de Crowdfunding. Registered investors may learn more financial information about ZeClinic’s campaign here. The campaign closes 31 May 2015.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!